Leads Biolabs Grants License for Inhaled Delivery of its Immunotherapies
publication date: May 16, 2019
Leads Biolabs of Maryland, a fully-owned subsidiary of a US-China JV, Nanjing Leads Biolabs, granted Pneuma Respiratory an exclusive license to develop Leads' panel of immuno-oncology mAbs and fusion protein molecules for pulmonary delivery. Pneuma, based in North Carolina, has developed a proprietary breath-activated digital inhaler. Using the inhaler, Pneuma will develop Leads' immuno-oncology therapies for pulmonary delivery to treat oncologic or immune-mediated lung diseases. Leads has developed a portfolio of more than ten novel mono or bispecific antibodies for cancer immunotherapy and other major diseases. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.